Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.13 -0.12 (-0.75%)
Streaming Delayed Price Updated: 3:53 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Why Summit Therapeutics Stock Slipped Today ↗
Via The Motley Fool
News headline image
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space. 
Via Benzinga
News headline image
Is Summit Therapeutics a Millionaire Maker? ↗
Via The Motley Fool
News headline image
This Unstoppable Biotech Stock Just Became an Even Better Buy ↗
Via The Motley Fool
News headline image
Is Summit Therapeutics a Millionaire Maker? ↗
Via The Motley Fool
News headline image
2 Stocks That Could Soar Again in 2025 ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Rocketed 584% in 2024 ↗
Via The Motley Fool
News headline image
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro... 
Via Benzinga
News headline image
Why Summit Therapeutics Stock Was Winning This Week ↗
Via The Motley Fool
News headline image
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year ↗
Via The Motley Fool
News headline image
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗
Via The Motley Fool
News headline image
Where Will Summit Therapeutics Be in 5 Years? ↗
Via The Motley Fool
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown ↗
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors. 
Via Stocktwits
News headline image
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday? ↗
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.  
Via Benzinga
Topics Stocks
News headline image
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
News headline image
Earnings Scheduled For February 24, 2025 ↗
 
Via Benzinga
News headline image
3 Stocks That Could Trounce the Market in 2025 ↗
Via The Motley Fool
News headline image
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec." 
Via Benzinga
News headline image
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? ↗
12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Stock Is Jumping Today ↗
Via The Motley Fool
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗
Via The Motley Fool
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.